Treatment of Anxiety Disorders - The Role of Pharmacists

1. American Psychological Association. Anxiey. Available at: http://www.apa.org/topics/anxiety/.Search in Google Scholar

2. Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013; 43(5): 897-910.10.1017/S003329171200147X22781489Search in Google Scholar

3. Remes O, Brayne C, van der Linde R, Lafortune L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016; 6(7): e00497.10.1002/brb3.497495162627458547Search in Google Scholar

4. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013;12(2): 92-98.10.1002/wps.20050368325123737408Search in Google Scholar

5. Roy-Byrne P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci. 2015; 17(2): 191-206.10.31887/DCNS.2015.17.2/proybyrneSearch in Google Scholar

6. Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol. 2007; 26(6): 872-8.10.1007/s10067-006-0407-y16941197Search in Google Scholar

7. Baqutayan SM. The effect of anxiety on breast cancer patients. Indian J Psychol Med. 2012; 34(2): 119-23.10.4103/0253-7176.101774349877223162185Search in Google Scholar

8. Olatunji BO, Cisler JM, Deacon BJ. Efficacy of cognitive behavioral therapy for anxiety disorders: a review of meta-analytic findings. Psychiatr Clin North Am. 2010; 33(3): 557-577.10.1016/j.psc.2010.04.00220599133Search in Google Scholar

9. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice. 2012; 16: 77-84.10.3109/13651501.2012.66711422540422Search in Google Scholar

10. Schaffer A, McIntosh D, Goldstein BI, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012; 24(1): 6-22.Search in Google Scholar

11. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry. 2009; 9: 38.10.1186/1471-244X-9-38270237719531229Search in Google Scholar

12. Monheit B, Pietrzak D, Hocking S. Prescription drug abuse - A timely update. Aust Fam Physician. 2016; 45(12): 862-866.Search in Google Scholar

13. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013. Am J Public Health. 2016; 106(4): 686-8.10.2105/AJPH.2016.303061481601026890165Search in Google Scholar

14. Stein MB, Roy-Byrne PP, Craske MG, et al Quality of and patient satisfaction with primary health care for anxiety disorders. J Clin Psychiatry. 2011; 72(7): 970-976.10.4088/JCP.09m05626blu311181421367351Search in Google Scholar

15. Woodward SC, Bereznicki BJ, Westbury JL, Bereznicki LR. The effect of knowledge and expectations on adherence to and persistence with antidepressants. Patient Prefer Adherence. 2016; 10: 761-8.10.2147/PPA.S99803486682927226710Search in Google Scholar

16. Rubio-Valera M, Serrano-Blanco A, Travé P, Peñarrubia-María MT, Ruiz M, Pujol MM. Community Pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol. BMC Public Health. 2009; 9: 284.10.1186/1471-2458-9-284273175019656386Search in Google Scholar

17. Wright WA, Gorman JM, Odorzynski M, Peterson MJ, Clayton C. Integrated Pharmacies at Community Mental Health Centers: Medication Adherence and Outcomes. J Manag Care Spec Pharm. 2016; 22(11): 1330-1336.10.18553/jmcp.2016.1600427783555Search in Google Scholar

18. Freccero C, Sundquist K, Sundquist J, Ji J. Primary adherence to antidepressant prescriptions in primary health care: a population-based study in Sweden. Scand J Prim Health Care. 2016; 34(1): 83-8.10.3109/02813432.2015.1132884491102826828942Search in Google Scholar

19. Klang SH, Ben-Amnon Y, Cohen Y, Barak Y. Community Pharmacists’ support improves antidepressant adherence in the community. Int Clin Psychopharmacol. 2015; 30(6): 316-9.10.1097/YIC.000000000000009026163876Search in Google Scholar

20. Bystritsky A, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and treatment of anxiety disorders. PT. 2013; 38(1): 30-57.Search in Google Scholar

21. Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2001; 62(Suppl 11): 46-50.Search in Google Scholar

22. Ravindran LN., Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010; 71(7): 839-854.10.4088/JCP.10r06218blu20667290Search in Google Scholar

23. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry. 2008; 9(4): 248-312.10.1080/1562297080246580718949648Search in Google Scholar

24. Pešić S. Antidepresivi i stabilizatori raspoloženja. In: Janković S. Farmakologija i toksikologija. 3th ed. Kragujevac: Medicinski fakultet. 2011: 217-34.Search in Google Scholar

25. Misri S, Burgmann A, Kostaras D. Are SSRIs safe for pregnant and breastfeeding women? Can Fam Physician. 2000; 46: 626-8, 631-3.Search in Google Scholar

26. Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014; 12(1): 44-56.10.2174/1570159X1201140117162802391534924533015Search in Google Scholar

27. Ryvlin P, Perucca E, Rheims S. Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat. 2008; 4(6): 1211-24.10.2147/NDT.S4716264665019337461Search in Google Scholar

28. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013; 9: 883-92.10.2147/NDT.S36453Search in Google Scholar

29. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey of reported prescribing practice in the treatment of patients with generalized anxiety disorder. World J Biol Psychiatry. 2012; 13(7): 510-516.10.3109/15622975.2011.624548Search in Google Scholar

30. Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007; 3(2): 185-91.10.2147/nedt.2007.3.2.185Search in Google Scholar

31. Patorno E, Bateman BT, Huybrechts KF, et al. Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology. 2017; 88(21): 2020-2025.10.1212/WNL.0000000000003959Search in Google Scholar

32. de Mesmaeker S, Zdanowicz N, Reynaert C, Jacques D. Role of benzodiazepines in the treatment of anxiety disorders in 2014. Psychiatr Danub. 2014; 26 Suppl 1: 23-6.Search in Google Scholar

33. Susman J, Klee B. The Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder. Prim Care Companion J Clin Psychiatry. 2005; 7(1): 5-11.10.4088/PCC.v07n0101Search in Google Scholar

34. Stevens JC, Pollack MH. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. J Clin Psychiatry. 2005; 66 Suppl 2: 21-7.Search in Google Scholar

35. Benzodiazepines: Revisiting Clinical Issues in Treating Anxiety Disorders. Prim Care Companion J Clin Psychiatry. 2005; 7(1): 23-32.10.4088/PCC.v07n0104Search in Google Scholar

36. Anxieties.com. Benzodiazepines (BZs). Available at: https://www.anxieties.com/157/benzodiazepinesbzs#.XCioR1xKjIU. Last time visited: Last time visited: 30.10.2018.Search in Google Scholar

37. Jovic Z. Anksiolitici (sedativi-hipnotici). In: Janković S. Farmakologija i toksikologija. 3th ed. Kragujevac: Medicinski fakultet 2011:178-94.Search in Google Scholar

38. Hayes PE, Schulz SC. Beta-blockers in anxiety disorders. J Affect Disord. 1987; 13(2): 119-30.10.1016/0165-0327(87)90017-6Search in Google Scholar

39. Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol 2016; 30(2): 128-39.10.1177/0269881115612236472479426487439Search in Google Scholar

40. Anxieties.com. Beta blockers. Available at:https://www.anxieties.com/159/betablockers#.XCj_VFxKjIU.Search in Google Scholar

41. Zohar J, Westenberg HG. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl. 2000; 403: 39-49.10.1111/j.1600-0447.2000.tb10947.x11019934Search in Google Scholar

42. Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin Drug Saf. 2014; 13(2): 207-25.10.1517/14740338.2014.86958224383525Search in Google Scholar

43. Hamann J, Linde K, Schweiger HD, Kusmakow O, Förstl H. Over-the-counter-drugs for the treatment of mood and anxiety disorders-the views of German pharmacists. Pharmacopsychiatry. 2014; 47(3): 84-8.10.1055/s-0034-137181024652700Search in Google Scholar

44. Sarris J, Stough C, Bousman CA, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psycho-pharmacol. 2013; 33(5): 643-8.10.1097/JCP.0b013e318291be6723635869Search in Google Scholar

45. Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J. 2010; 9: 42.10.1186/1475-2891-9-42295908120929532Search in Google Scholar

46. Nunes A, Sousa M. [Use of valerian in anxiety and sleep disorders: what is the best evidence?]. Acta Med Port 2011;24 Suppl 4:961-6.Search in Google Scholar

47. World Health Organization. Improving Access And Use Of Psychotropic Medicines. Available at: http://apps.who.int/iris/bitstream/handle/10665/42883/9241546417.pdf.Search in Google Scholar

48. Vilarim MM, Rocha Araujo DM, Nardi AE. Caffeine challenge test and panic disorder: a systematic literature review. Exp Rev Neurotherapeutics. 2011; 11(8): 1185-1195.10.1586/ern.11.8321797659Search in Google Scholar

49. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009; 24(7): 515-523.10.1002/hup.104819693792Search in Google Scholar

50. Roy-Byrne PP, Uhde TW, Post RM. Effects of one night’s sleep deprivation on mood and behavior in panic disorder. Patients with panic disorder compared with depressed patients and normal controls. Arch Gen Psychiatry. 1986; 43(9): 895-899.10.1001/archpsyc.1986.018000900850113753167Search in Google Scholar

51. Wright WA, Gorman JM, Odorzynski M, Peterson MJ, Clayton C. Integrated Pharmacies at Community Mental Health Centers: Medication Adherence and Outcomes. J Manag Care Spec Pharm. 2016; 22(11): 1330-1336.10.18553/jmcp.2016.1600427783555Search in Google Scholar

52. Murphy AL, Gardner DM, Jacobs LM. Patient care activities by community Pharmacists in a capitation funding model mental health and addictions program. BMC Psychiatry. 2018; 18(1): 192.10.1186/s12888-018-1746-3600092729898682Search in Google Scholar

53. Martin P, Tamblyn R, Ahmed S, et al. An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial. Trials. 2013; 14(1): 80.10.1186/1745-6215-14-80362109923514019Search in Google Scholar

54. Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014; 77(2): 295-301.10.1111/j.1365-2125.2012.04418.x401401522882333Search in Google Scholar

55. Raynor DK, Dickinson R, Knapp P, Long AF, Nicolson DJ. Buyer beware? Does the information provided with herbal products available over-the-counter enable safe use? BMC Med. 2011; 9: 94.10.1186/1741-7015-9-94Search in Google Scholar

56. Di Y M, Li C G, Xue C C et al. Clinical drugs that interact with St. John’s wort and implication in drug development. Curr Pharm Des. 2008; 14: 1723-1742.10.2174/13816120878474679818673195Search in Google Scholar

57. Stickel F, Shouval D. Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol. 2015; 89(6): 851-65.10.1007/s00204-015-1471-325680499Search in Google Scholar

58. Milosavljevic MN, Stefanovic SM, Milosavljevic MN, Kocovic AG, Jankovic SM. Uloga farmaceuta u prevenciji i otkrivanju interakcija OTC preparata: tehnika nominalne grupe. Racionalna terapija. 2018; 10(1): 1-12.10.5937/racter10-14500Search in Google Scholar